Chavez-Tapia NC, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 14
Paginas: 163-165
Archivo PDF: 56.76 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Landells LJ, Naidoo B, Robertson J, Clark P. NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis. Lancet Respir Med 2013; 1: 191-2.

2. Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V, Armendariz-Borunda J. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 2012; 678:71-7.

3. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-5.

4. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One 2012; 7: e47024.

5. Klein R. A new paradigm for funding medical research. Stem Cells Transl Med 2012; 1: 3-5.

6. Puggal MA, Schully SD, Srinivas PR, Papanicolaou GJ, Jaquish CE, Fabsitz RR. Translation of genetics research to clinical medicine: the national heart, lung, and blood institute perspective. Circ Cardiovasc Genet 2013;6:634-639.

7. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. Bmj 2002; 325: 269-71.

8. Apolone G. Clinical and outcome research in oncology. The need for integration. Health Qual Life Outcomes 2003; 1: 3.

9. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: metaepidemiological study. Bmj 2013; 346: f2304.

10. Inthout J, Ioannidis JP, Borm GF. Obtaining evidence by a single well-powered trial or several modestly powered trials. Stat Methods Med Res 2012; Oct 14. [Epub ahead of print].

11. Oberfeld D, Franke T. Evaluating the robustness of repeated measures analyses: the case of small sample sizes and nonnormal data. Behav Res Methods 2013; 45: 792-812.

12. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

13. Ledford H. Pharma scrambles to fast-track drugs. Nature 2013; 502: 20.

14. Rich EC. From methods to policy: Primum non nocere: reconciling patient-centered outcomes with evidence-based care. J Comp Eff Res 2013; 2: 107-8.